Grades of recommendation for antithrombotic agents

Chest

Volumn 119, Issue 1 SUPPL., 2001, Pages 3S-7S

  Guyatt, G ^a   Schunemann H ^a   Cook, D ^a   Jaeschke, R ^a   Pauker, S ^a   Bucher, H ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

AGING; ANTICOAGULANT THERAPY; CARDIOVASCULAR RISK; CEREBELLUM DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; METHODOLOGY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT INDICATION;

EID: 0035125452     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.1_suppl.3S     Document Type: Conference Paper

References (9)

1. Rules of evidence and clinical recommendations on the use of antithrombotic agents
2. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events
3. Users' guides to the medical literature: IX. A method for grading health care recommendations
4. Users' guides to the medical literature: XVI. How to use a treatment recommendation
5. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction
6. Coronary thrombolysis
7. Prevention of venous thromboembolism
8. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation
9. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: Systematic overview of randomised trials